Tags

Type your tag names separated by a space and hit enter

Chondroitin sulfate and/or glucosamine hydrochloride for Kashin-Beck disease: a cluster-randomized, placebo-controlled study.
Osteoarthritis Cartilage. 2012 Jul; 20(7):622-9.OC

Abstract

OBJECTIVE

To evaluate the efficacy and safety of chondroitin sulfate and/or glucosamine hydrochloride in alleviating symptoms and improving the dysfunction of Kashin-Beck disease (KBD) patients.

METHODS

We undertook a cluster-randomized, placebo-controlled trial in 251 patients with KBD. Participants were randomly allocated to comparing (1) chondroitin sulfate, (2) glucosamine hydrochloride, (3) a combination of chondroitin sulfate and glucosamine hydrochloride, or (4) placebo, for 6 months duration. The primary outcome measures of interest were 20% and 50% reductions in pain from baseline, measured by pain subscale in the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index. Secondary outcome measures included parameters in the WOMAC Index such as pain, stiffness, and physical function, as well as patients' quality of life by the 12-item Short-Form General Health Survey. The trial registration number is ChiCTR-TRC-11001480 (http://www.chictr.org/).

RESULTS

A combination therapy of chondroitin sulfate and glucosamine hydrochloride was effective in reducing WOMAC pain by 20% (differences of 23.4%, P=0.006) and 50% (differences of 15.7%, P=0.016), WOMAC pain (P=0.032), WOMAC stiffness (P=0.043), and WOMAC total score (P=0.035). Chondroitin sulfate used alone was also found to be effective in reducing WOMAC total score and stiffness score (P=0.038 and P=0.023, respectively). No significant positive effects in improving WOMAC Index scores were observed with glucosamine hydrochloride alone.

CONCLUSION

The findings of this study indicate that a combination of chondroitin sulfate and glucosamine hydrochloride was more effective than placebo in treating KBD.

Authors+Show Affiliations

West China Hospital, Sichuan University, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22469850

Citation

Yue, J, et al. "Chondroitin Sulfate And/or Glucosamine Hydrochloride for Kashin-Beck Disease: a Cluster-randomized, Placebo-controlled Study." Osteoarthritis and Cartilage, vol. 20, no. 7, 2012, pp. 622-9.
Yue J, Yang M, Yi S, et al. Chondroitin sulfate and/or glucosamine hydrochloride for Kashin-Beck disease: a cluster-randomized, placebo-controlled study. Osteoarthr Cartil. 2012;20(7):622-9.
Yue, J., Yang, M., Yi, S., Dong, B., Li, W., Yang, Z., Lu, J., Zhang, R., & Yong, J. (2012). Chondroitin sulfate and/or glucosamine hydrochloride for Kashin-Beck disease: a cluster-randomized, placebo-controlled study. Osteoarthritis and Cartilage, 20(7), 622-9. https://doi.org/10.1016/j.joca.2012.03.013
Yue J, et al. Chondroitin Sulfate And/or Glucosamine Hydrochloride for Kashin-Beck Disease: a Cluster-randomized, Placebo-controlled Study. Osteoarthr Cartil. 2012;20(7):622-9. PubMed PMID: 22469850.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chondroitin sulfate and/or glucosamine hydrochloride for Kashin-Beck disease: a cluster-randomized, placebo-controlled study. AU - Yue,J, AU - Yang,M, AU - Yi,S, AU - Dong,B, AU - Li,W, AU - Yang,Z, AU - Lu,J, AU - Zhang,R, AU - Yong,J, Y1 - 2012/03/30/ PY - 2011/09/03/received PY - 2012/03/11/revised PY - 2012/03/21/accepted PY - 2012/4/4/entrez PY - 2012/4/4/pubmed PY - 2012/9/6/medline SP - 622 EP - 9 JF - Osteoarthritis and cartilage JO - Osteoarthr. Cartil. VL - 20 IS - 7 N2 - OBJECTIVE: To evaluate the efficacy and safety of chondroitin sulfate and/or glucosamine hydrochloride in alleviating symptoms and improving the dysfunction of Kashin-Beck disease (KBD) patients. METHODS: We undertook a cluster-randomized, placebo-controlled trial in 251 patients with KBD. Participants were randomly allocated to comparing (1) chondroitin sulfate, (2) glucosamine hydrochloride, (3) a combination of chondroitin sulfate and glucosamine hydrochloride, or (4) placebo, for 6 months duration. The primary outcome measures of interest were 20% and 50% reductions in pain from baseline, measured by pain subscale in the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index. Secondary outcome measures included parameters in the WOMAC Index such as pain, stiffness, and physical function, as well as patients' quality of life by the 12-item Short-Form General Health Survey. The trial registration number is ChiCTR-TRC-11001480 (http://www.chictr.org/). RESULTS: A combination therapy of chondroitin sulfate and glucosamine hydrochloride was effective in reducing WOMAC pain by 20% (differences of 23.4%, P=0.006) and 50% (differences of 15.7%, P=0.016), WOMAC pain (P=0.032), WOMAC stiffness (P=0.043), and WOMAC total score (P=0.035). Chondroitin sulfate used alone was also found to be effective in reducing WOMAC total score and stiffness score (P=0.038 and P=0.023, respectively). No significant positive effects in improving WOMAC Index scores were observed with glucosamine hydrochloride alone. CONCLUSION: The findings of this study indicate that a combination of chondroitin sulfate and glucosamine hydrochloride was more effective than placebo in treating KBD. SN - 1522-9653 UR - https://www.unboundmedicine.com/medline/citation/22469850/Chondroitin_sulfate_and/or_glucosamine_hydrochloride_for_Kashin_Beck_disease:_a_cluster_randomized_placebo_controlled_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1063-4584(12)00763-7 DB - PRIME DP - Unbound Medicine ER -